Targets and mechanisms of chemically induced aneuploidy. Part 1 of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases

Mutat Res Genet Toxicol Environ Mutagen. 2019 Nov:847:403025. doi: 10.1016/j.mrgentox.2019.02.006. Epub 2019 Mar 2.

Abstract

An aneuploidy workgroup was established as part of the 7th International Workshops on Genotoxicity Testing. The workgroup conducted a review of the scientific literature on the biological mechanisms of aneuploidy in mammalian cells and methods used to detect chemical aneugens. In addition, the current regulatory framework was discussed, with the objective to arrive at consensus statements on the ramifications of exposure to chemical aneugens for human health risk assessment. As part of these efforts, the workgroup explored the use of adverse outcome pathways (AOPs) to document mechanisms of chemically induced aneuploidy in mammalian somatic cells. The group worked on two molecular initiating events (MIEs), tubulin binding and binding to the catalytic domain of aurora kinase B, which result in several adverse outcomes, including aneuploidy. The workgroup agreed that the AOP framework provides a useful approach to link evidence for MIEs with aneuploidy on a cellular level. The evidence linking chemically induced aneuploidy with carcinogenicity and hereditary disease was also reviewed and is presented in two companion papers. In addition, the group came to the consensus that the current regulatory test batteries, while not ideal, are sufficient for the identification of aneugens and human risk assessment. While it is obvious that there are many different MIEs that could lead to the induction of aneuploidy, the most commonly observed mechanisms involving chemical aneugens are related to tubulin binding and, to a lesser extent, inhibition of mitotic kinases. The comprehensive review presented here should help with the identification and risk management of aneugenic agents.

Publication types

  • Consensus Development Conference
  • Review

MeSH terms

  • Adverse Outcome Pathways*
  • Aneuploidy*
  • Animals
  • Aurora Kinase B / antagonists & inhibitors
  • Aurora Kinase B / physiology
  • Carcinogens / toxicity
  • Chromosome Aberrations / chemically induced
  • Chromosome Segregation / drug effects
  • Chromosomes / drug effects
  • Genes, Reporter
  • Genetic Diseases, Inborn / chemically induced*
  • Genetic Diseases, Inborn / genetics
  • Germ Cells / drug effects
  • Germ Cells / ultrastructure
  • Humans
  • Mice
  • Micronucleus Tests
  • Microtubules / drug effects
  • Mitosis / drug effects*
  • Mitosis / physiology
  • Mutagenicity Tests / methods*
  • Mutagenicity Tests / standards
  • Mutagens / analysis
  • Mutagens / toxicity*
  • Neoplasms / chemically induced*
  • Neoplasms / genetics
  • Nondisjunction, Genetic / drug effects
  • Risk Management / legislation & jurisprudence
  • Tubulin Modulators / toxicity

Substances

  • Carcinogens
  • Mutagens
  • Tubulin Modulators
  • Aurora Kinase B